This session was held on November 21 2023, during the 34rd Regional ISBT Congress that was held in Cape Town, South Africa from November 18-21, 2023.
The Advances in conventional components session included the following presentations:
1. Jose Cancelas: A perspective: freeze-dried blood products
2. Muluken Kassahun: Quality assessment of platelet concentrates prepared from different time held whole blood at Ethiopian Blood and Tissue Bank Service, Addis Ababa
3. Adriaan Meyer: An in vitro comparison of red blood cells haemolysis in neocyte-enriched and leucocyte-poor blood
MODERATORS: Shaldine Sutton, Jason Acker
Abstract
A perspective: Freeze-dried blood products
J Cancelas1
1Hoxworth Blood Center, University of Cincinnati, Cincinnati, United States
Hemorrhage is a major cause of preventable death in trauma and cancer. Trauma induced coagulopathy and cancer-associated endotheliopathy remain major therapeutic challenges. Early, aggressive administration of blood-derived products with increased clotting profile potential has been proposed. A series of clinical trials testing the safety and/or efficacy of lyophilized plasma and platelet products have provided light on the future of alternative blood component therapies. A group of next-generation freeze-dried and spray-dried plasma products as well as lyophilized platelet products, in different stages of clinical development, offer long-term shelf-lives and significant logistical advantages in the treatment of patients in austere environments and/or underdeveloped healthcare regions. This presentation will provide a review of the information provided by the most recent clinical trials testing the safety and/or efficacy of lyophilized plasma or platelets.
